Shares of Nuvation Bio (NUVB 14.91%) were skyrocketing 15.7% higher as of 11:20 a.m. ET on Tuesday. The big jump came after two positive developments for the cancer-focused drugmaker.
Nuvation Bio announced on Tuesday morning that it has enrolled the first patient in its phase 3 clinical study evaluating Ibtrozi (taletrectinib) for the treatment of resected ROS1-positive early stage non-small cell lung cancer (NSCLC). Also, Jefferies (JEF -1.65%) initiated coverage on Nuvation Bio with a buy rating. The investment banking and capital markets company set a price target for the stock of $10, reflecting an upside potential of roughly 210% from Nuvation's closing price on Monday, Sept. 29, 2025.
Nuvation Bio probably won't be a great fit for risk-averse investors. Although the company received U.S. regulatory approval for Ibtrozi in June 2025 for treating locally advanced or metastatic ROS1+ NSCLC, it's a one-trick pony for now -- and an unprofitable one.
https://www.fool.com/investing/2025/09/30/why-nuvation-bio-stock-is-skyrocketing-today/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.